MY183969A - Combination of regorafenib and acetylsalicylic acid for treating cancer - Google Patents
Combination of regorafenib and acetylsalicylic acid for treating cancerInfo
- Publication number
- MY183969A MY183969A MYPI2015700911A MYPI2015700911A MY183969A MY 183969 A MY183969 A MY 183969A MY PI2015700911 A MYPI2015700911 A MY PI2015700911A MY PI2015700911 A MYPI2015700911 A MY PI2015700911A MY 183969 A MY183969 A MY 183969A
- Authority
- MY
- Malaysia
- Prior art keywords
- regorafenib
- acetylsalicylic acid
- combination
- treating cancer
- cancer
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004836 regorafenib Drugs 0.000 title abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title 1
- 229960001138 acetylsalicylic acid Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185852 | 2012-09-25 | ||
| PCT/EP2013/069735 WO2014048881A1 (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY183969A true MY183969A (en) | 2021-03-17 |
Family
ID=46963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015700911A MY183969A (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10898500B2 (https=) |
| EP (1) | EP2900269B1 (https=) |
| JP (1) | JP6294888B2 (https=) |
| KR (1) | KR102210575B1 (https=) |
| CN (1) | CN104994876A (https=) |
| AU (1) | AU2013322854B2 (https=) |
| BR (1) | BR112015006686B1 (https=) |
| CA (1) | CA2885688C (https=) |
| CL (1) | CL2015000744A1 (https=) |
| CY (1) | CY1120939T1 (https=) |
| DK (1) | DK2900269T3 (https=) |
| EA (1) | EA032023B1 (https=) |
| ES (1) | ES2687985T3 (https=) |
| HK (1) | HK1214169A1 (https=) |
| HR (1) | HRP20181462T1 (https=) |
| HU (1) | HUE039878T2 (https=) |
| IL (1) | IL237690B (https=) |
| LT (1) | LT2900269T (https=) |
| MX (1) | MX357035B (https=) |
| MY (1) | MY183969A (https=) |
| NZ (1) | NZ705860A (https=) |
| PH (1) | PH12015500587A1 (https=) |
| PL (1) | PL2900269T3 (https=) |
| PT (1) | PT2900269T (https=) |
| RS (1) | RS57875B1 (https=) |
| SG (2) | SG11201501963RA (https=) |
| SI (1) | SI2900269T1 (https=) |
| WO (1) | WO2014048881A1 (https=) |
| ZA (1) | ZA201502840B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN09346A (https=) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| KR102179599B1 (ko) | 2012-09-25 | 2020-11-19 | 에프. 호프만-라 로슈 아게 | 이환형 유도체 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CN105764905B (zh) | 2013-11-26 | 2019-06-07 | 豪夫迈·罗氏有限公司 | 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基 |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| CN104829523B (zh) * | 2014-04-30 | 2017-10-31 | 药源药物化学（上海）有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| KR20180054830A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서의 이환형 화합물 |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| WO2018002124A1 (en) * | 2016-06-28 | 2018-01-04 | Asamedic As | Two-component composition |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| PE20200859A1 (es) * | 2017-06-02 | 2020-08-25 | Bayer Healthcare Llc | Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno |
| EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
| EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1197228A4 (en) * | 1999-07-02 | 2004-03-10 | Hisamitsu Pharmaceutical Co | DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER |
| US20040121004A1 (en) | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| EA010485B1 (ru) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| JP2009514921A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 糖尿病性神経障害を処置するためのジアリールウレア |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| GB201002530D0 (en) * | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
-
2013
- 2013-09-23 US US14/431,119 patent/US10898500B2/en active Active
- 2013-09-23 CA CA2885688A patent/CA2885688C/en active Active
- 2013-09-23 SG SG11201501963RA patent/SG11201501963RA/en unknown
- 2013-09-23 HU HUE13770659A patent/HUE039878T2/hu unknown
- 2013-09-23 PL PL13770659T patent/PL2900269T3/pl unknown
- 2013-09-23 DK DK13770659.4T patent/DK2900269T3/en active
- 2013-09-23 WO PCT/EP2013/069735 patent/WO2014048881A1/en not_active Ceased
- 2013-09-23 EP EP13770659.4A patent/EP2900269B1/en active Active
- 2013-09-23 CN CN201380050150.7A patent/CN104994876A/zh active Pending
- 2013-09-23 MX MX2015003728A patent/MX357035B/es active IP Right Grant
- 2013-09-23 ES ES13770659.4T patent/ES2687985T3/es active Active
- 2013-09-23 SI SI201331181T patent/SI2900269T1/sl unknown
- 2013-09-23 RS RS20181015A patent/RS57875B1/sr unknown
- 2013-09-23 HK HK16102326.3A patent/HK1214169A1/zh unknown
- 2013-09-23 PT PT13770659T patent/PT2900269T/pt unknown
- 2013-09-23 BR BR112015006686-0A patent/BR112015006686B1/pt active IP Right Grant
- 2013-09-23 KR KR1020157010519A patent/KR102210575B1/ko active Active
- 2013-09-23 JP JP2015532437A patent/JP6294888B2/ja active Active
- 2013-09-23 EA EA201500365A patent/EA032023B1/ru not_active IP Right Cessation
- 2013-09-23 MY MYPI2015700911A patent/MY183969A/en unknown
- 2013-09-23 LT LTEP13770659.4T patent/LT2900269T/lt unknown
- 2013-09-23 AU AU2013322854A patent/AU2013322854B2/en active Active
- 2013-09-23 SG SG10201702356VA patent/SG10201702356VA/en unknown
- 2013-09-23 NZ NZ705860A patent/NZ705860A/en unknown
- 2013-09-23 HR HRP20181462TT patent/HRP20181462T1/hr unknown
-
2015
- 2015-03-12 IL IL237690A patent/IL237690B/en active IP Right Grant
- 2015-03-17 PH PH12015500587A patent/PH12015500587A1/en unknown
- 2015-03-24 CL CL2015000744A patent/CL2015000744A1/es unknown
- 2015-04-24 ZA ZA2015/02840A patent/ZA201502840B/en unknown
-
2018
- 2018-09-20 CY CY181100976T patent/CY1120939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| IN2014DN09434A (https=) | ||
| MX365702B (es) | Inhibidores de pirazolil quinoxalina cinasa. | |
| WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
| PH12015500460B1 (en) | Coated pharmaceutical composition containing regorafenib | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| IN2014DN09352A (https=) | ||
| EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
| NZ720478A (en) | Autotaxin inhibitor compounds | |
| MX349004B (es) | Nuevos compuestos. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| TN2015000280A1 (en) | Topical Ophthalmological Pharmaceutical Composition containing Regorafenib | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| WO2014138616A3 (en) | Pyrazole compounds and methods of use thereof | |
| AU2012312301A8 (en) | Compounds useful as inhibitors of choline kinase |